Kris on Oncology

• We're in a 'Brave New World' of Low-Grade Toxicities   Mark Kris, MD, discusses the implications of long-term toxicities with TKI therapy.
  Medscape Oncology, November 07, 2023
• NSCLC: Case for Combining Chemo and Osimertinib   Mark G. Kris, MD, discusses perioperative therapy for locally advanced lung cancer and the potential implications for survival and cure.
  Medscape Oncology, November 01, 2023
• How to Think About Second-Line Therapy in NSCLC   Mark G. Kris, MD, discusses second-line therapy for non–small cell lung cancers.
  Medscape Oncology, October 31, 2023
  2
• Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer   Mark G. Kris, MD, discusses neoadjuvant therapy for patients with locally advanced lung cancers.
  Medscape Oncology, October 17, 2023
• Add Chemo for Fit Patients With EGFR-Mutant Lung Cancer   Mark Kris, MD, discusses the addition of chemotherapy for newly diagnosed EGFR-mutant lung cancers.
  Medscape Oncology, October 02, 2023
• New 'C Word': Cure Should Be Goal for Lung Cancer Patients   Mark G. Kris, MD, discusses the need for cure as a goal of care for patients with lung cancer.
  Medscape Oncology, September 19, 2023
  3
• New Lung Cancer Data: Focus on the Positive   Mark G. Kris, MD, discusses advances in treating patients with lung cancer as reported at ASCO 2023.
  Medscape Oncology, September 18, 2023
• Similar DFS With Sublobar Resection: We Must Do More   Mark G. Kris, MD, discusses a recent paper and accompanying editorial on the similar observed disease-free benefits with sublobar and lobar resection.
  Medscape Oncology, July 18, 2023
• Immigrants in Healthcare: Culturally Diverse Patients   Mark G. Kris, MD, discusses an article written by Dr April Choi, focused on care of patients from different cultural backgrounds.
  Medscape Oncology, May 15, 2023
  1
• Locally Advanced NSCLC: How to Optimize Your Tumor Board   Mark G. Kris, MD, discusses multidisciplinary tumor board decision making.
  Medscape Oncology, March 15, 2023
• Standard-of-Care Therapy in Lung Cancer: Be Open to New Ideas   Dr Mark Kris discusses topics for consideration brought up during a meeting of thoracic oncology practitioners.
  Medscape Oncology, February 27, 2023
  1
• A Care-Related Wish List: Lessons From the Pandemic   Mark G. Kris, MD, discusses a wish list of important care-related considerations.
  Medscape Oncology, February 27, 2023
• Top Questions When Treating Resectable NSCLC   Dr Mark Kris discusses topics of interest and insights that emerged from a meeting of thoracic oncology practitioners.
  Medscape Oncology, February 24, 2023
• Postop RT: Meaningful Survival Improvement in N2 Lung Cancer   Dr Mark Kris discusses the use of postoperative radiation therapy in patients with N2 disease.
  Medscape Oncology, February 23, 2023
• Disease-Free Survival: Endpoint for Adjuvant Therapy for Cancer?   Mark Kris, MD, discusses a recent article on the use of disease-free survival as a clinical endpoint.
  Medscape Oncology, February 22, 2023
  1
• Checkpoint Inhibitor Retreatment After Relapse Helps Few   Mark Kris, MD, discusses whether there is a role for retreatment with a checkpoint inhibitor after relapse.
  Medscape Oncology, December 09, 2022
• In Early-Stage NSCLC, Give Nivolumab Before or After Surgery?   Dr Mark Kris discusses the choice between neoadjuvant and adjuvant nivolumab for patients with early-stage lung cancer.
  Medscape Oncology, December 09, 2022
• Where Are Checkpoint Inhibitors Standard of Care for NSCLC?   Dr Mark Kris discusses the use of checkpoint inhibitors in the adjuvant and neoadjuvant settings for patients with non-small cell lung cancer.
  Medscape Oncology, December 09, 2022
• ASCO 2022 Myth Busting: Do Systemic Therapies Affect Brain Metastases?   Dr Mark Kris discusses abstracts from ASCO 2022 demonstrating similar effects of systematic therapies for lung cancers on brain metastases.
  Medscape Oncology, December 08, 2022
• How to Select Treatment for Resectable Stage III Lung Cancer   Dr Mark Kris discusses treatment options for patients with stage III lung cancer.
  Medscape Oncology, September 19, 2022